NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

Shares of GSK PLC GSK rose 1.79% to £14.47 Thursday, on what proved to be an all-around rough trading session for the stock ...

(Alliance News) - GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China.

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

Valeo Financial Advisors LLC lowered its position in GSK plc (NYSE:GSK – Free Report) by 31.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

(Alliance News) - Hedge fund Citadel has made a GBP305 million bet against pharmaceuticals firm GSK PLC, the biggest short position against the company in more than a decade, according to the ...

GSK plc (LON:GSK – Get Free Report) insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction on Monday, ...